Buy Rating Reaffirmed on Lymphir’s Growing Commercial Momentum and CTCL Market Upside; $4 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Michael Okunewitch reaffirmed a Buy rating on Citius Oncology with a $4 price target. The decision is driven by Lymphir's growing commercial momentum, including increased institutional adoption and vial shipments. Okunewitch anticipates faster revenue growth in fiscal 2016 due to broad formulary access and favorable dynamics in the cutaneous T-cell lymphoma market, where novel agents are often added rather than substituted.
Maxim Group analyst Michael Okunewitch maintained a Buy rating on Citius Oncology yesterday and set a price target of $4.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Michael Okunewitch has given his Buy rating due to a combination of factors tied to the early commercial momentum of Lymphir and its long-term revenue potential. He highlights that institutional adoption is building quickly, with a sharp rise in ordering centers and vial shipments, and expects this expanding base, together with broad formulary access, to translate into a faster revenue ramp in the second half of fiscal 2026.
He also underscores the attractive dynamics of the cutaneous T‑cell lymphoma market, where patients cycle through multiple therapies over long survival periods, allowing novel agents like Lymphir to be added rather than substituted. With management sizing the addressable opportunity up to roughly $400 million and historical analogs suggesting meaningful sales potential, he sees the current valuation as not fully reflecting this upside, supporting a Buy rating and an unchanged $4 price target.